273 related articles for article (PubMed ID: 32681294)
1. Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer.
Kaltofen T; Preinfalk V; Schwertler S; Fraungruber P; Heidegger H; Vilsmaier T; Vattai A; Czogalla B; Mayr D; Mahner S; Jeschke U; Trillsch F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2559-2574. PubMed ID: 32681294
[TBL] [Abstract][Full Text] [Related]
2. Emodin Inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer Cells via ILK/GSK-3
Lu J; Xu Y; Wei X; Zhao Z; Xue J; Liu P
Biomed Res Int; 2016; 2016():6253280. PubMed ID: 28097141
[TBL] [Abstract][Full Text] [Related]
3. BRMS1L suppresses ovarian cancer metastasis via inhibition of the β-catenin-wnt pathway.
Cao P; Zhao S; Sun Z; Jiang N; Shang Y; Wang Y; Gu J; Li S
Exp Cell Res; 2018 Oct; 371(1):214-221. PubMed ID: 30118697
[TBL] [Abstract][Full Text] [Related]
4. GOLPH3 induces epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in epithelial ovarian cancer.
Sun J; Yang X; Zhang R; Liu S; Gan X; Xi X; Zhang Z; Feng Y; Sun Y
Cancer Med; 2017 Apr; 6(4):834-844. PubMed ID: 28332316
[TBL] [Abstract][Full Text] [Related]
5. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
6. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
7. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis.
Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X
Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway.
Zhuang XH; Liu Y; Li JL
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31337688
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
[TBL] [Abstract][Full Text] [Related]
11. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
Duan H; Yan Z; Chen W; Wu Y; Han J; Guo H; Qiao J
Gynecol Oncol; 2017 Nov; 147(2):408-417. PubMed ID: 28851501
[TBL] [Abstract][Full Text] [Related]
12. DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy.
Li RN; Liu B; Li XM; Hou LS; Mu XL; Wang H; Linghu H
Sci Rep; 2017 Aug; 7(1):9285. PubMed ID: 28839145
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
14. Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer.
Bodnar L; Stanczak A; Cierniak S; Smoter M; Cichowicz M; Kozlowski W; Szczylik C; Wieczorek M; Lamparska-Przybysz M
J Ovarian Res; 2014 Feb; 7():16. PubMed ID: 24499657
[TBL] [Abstract][Full Text] [Related]
15. USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway.
Pei L; Zhao F; Zhang Y
Apoptosis; 2024 Feb; 29(1-2):210-228. PubMed ID: 38087046
[TBL] [Abstract][Full Text] [Related]
16. Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin.
Zhao H; Yang Z; Wang X; Zhang X; Wang M; Wang Y; Mei Q; Wang Z
Exp Mol Med; 2012 Nov; 44(11):633-41. PubMed ID: 22902510
[TBL] [Abstract][Full Text] [Related]
17. LY75 Ablation Mediates Mesenchymal-Epithelial Transition (MET) in Epithelial Ovarian Cancer (EOC) Cells Associated with DNA Methylation Alterations and Suppression of the Wnt/β-Catenin Pathway.
Mehdi S; Bachvarova M; Scott-Boyer MP; Droit A; Bachvarov D
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32156068
[TBL] [Abstract][Full Text] [Related]
18. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
[TBL] [Abstract][Full Text] [Related]
19. Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells.
Zhong Y; Le F; Cheng J; Luo C; Zhang X; Wu X; Xu F; Zuo Q; Tan B
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760192
[TBL] [Abstract][Full Text] [Related]
20. Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling.
Wu G; Cao L; Zhu J; Tan Z; Tang M; Li Z; Hu Y; Yu R; Zhang S; Song L; Li J
Clin Cancer Res; 2019 Feb; 25(3):1022-1035. PubMed ID: 30279231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
